Marketplace helps you stay financially responsible all year, now we need YOUR help to keep our budget on track.
Donate NOW to help us hit our target of 2,500 Marketplace Investors by June 30!
Alexion Pharmaceuticals announced this week it is buying Synageva Biopharma for $8.4 billion. Alexion develops so-called orphan drugs, treatments for rare diseases. In the U.S., rare diseases, most of them genetic, affect about 30 million people.
If you’re in the business of making drugs, you need people to sell them to. Even though the pool of people needing these treatments is smaller, the payoff is huge if you’re a rare disease drug company, says Adam Feuerstein. He’s senior columnist covering biotech at The Street.
“When you’re charging $500,000 a year, that adds up.” Feuerstein says. That’s per patient. He says that’s the main reason we’re seeing all these mergers and acquisitions lately in biopharma. “There are just relatively few drugs being developed that can generate hundreds of millions and billions in dollars in sales.”
Pete Mooney tracks the biotech industry for Deloitte. “So it does a very strong social good as well,” Mooney adds. He says also, governments have made this market lucrative, and they’ve removed lots of the roadblocks regular pharmaceutical companies face. So drugs get to market faster, and help people in need.
But, Mooney says, as always, companies have to balance the cost of developing these treatments with how affordable they’ll be for patients.
If you’re a member of your local public radio station, we thank you — because your support helps those stations keep programs like Marketplace on the air. But for Marketplace to continue to grow, we need additional investment from those who care most about what we do: superfans like you.
Your donation — as little as $5 — helps us create more content that matters to you and your community, and to reach more people where they are – whether that’s radio, podcasts or online.
When you contribute directly to Marketplace, you become a partner in that mission: someone who understands that when we all get smarter, everybody wins.